Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib and dexamethasone consolidation after SCT for multiple myeloma
NCT01812720Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Aug 2013
- Primary completion
- Sep 2014
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoint: Complete Response Rate at 5 years. Planned start Aug 2013; status: withdrawn.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01812720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812720.